Evidence map›Paper›PMID 42287172›Full record

ReviewTherapeutic delivery2026

Bile acids and nanotechnology as emerging platforms for drug delivery.

Le Yang Sen, Mikhaela Lorenzo, Mengistie Diress, Susbin Raj Wagle, Abril Mena Balborin, Bozica Kovacevic, Armin Mooranian, Hani Al-Salami

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Le Yang SenThe Biotechnology and Drug Development Research Laboratory, School of Diagnostic and Therapeutic Sciences & Curtin Medical Research Institute, Curtin University, Bentley, Western Australia, Australia.ORCID 0009-0000-8541-5747
Mikhaela LorenzoThe Biotechnology and Drug Development Research Laboratory, School of Diagnostic and Therapeutic Sciences & Curtin Medical Research Institute, Curtin University, Bentley, Western Australia, Australia.ORCID 0009-0006-0334-7124
Mengistie DiressThe Biotechnology and Drug Development Research Laboratory, School of Diagnostic and Therapeutic Sciences & Curtin Medical Research Institute, Curtin University, Bentley, Western Australia, Australia.ORCID 0000-0003-4186-4991
Susbin Raj WagleThe Biotechnology and Drug Development Research Laboratory, School of Diagnostic and Therapeutic Sciences & Curtin Medical Research Institute, Curtin University, Bentley, Western Australia, Australia.ORCID 0000-0001-9867-8896
Abril Mena BalborinThe Biotechnology and Drug Development Research Laboratory, School of Diagnostic and Therapeutic Sciences & Curtin Medical Research Institute, Curtin University, Bentley, Western Australia, Australia.
Bozica KovacevicThe Biotechnology and Drug Development Research Laboratory, School of Diagnostic and Therapeutic Sciences & Curtin Medical Research Institute, Curtin University, Bentley, Western Australia, Australia.ORCID 0000-0002-9359-7840
Armin MooranianThe Biotechnology and Drug Development Research Laboratory, School of Diagnostic and Therapeutic Sciences & Curtin Medical Research Institute, Curtin University, Bentley, Western Australia, Australia.ORCID 0000-0001-7103-2067
Hani Al-SalamiThe Biotechnology and Drug Development Research Laboratory, School of Diagnostic and Therapeutic Sciences & Curtin Medical Research Institute, Curtin University, Bentley, Western Australia, Australia.ORCID 0000-0003-0049-6969

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDrugs are generally classified according to the Biopharmaceutics Classification System (BCS) based on their solubility and intestinal permeability. Group I drugs tend to have higher bioavailability due to their high solubility and permeability. Drugs in group II have low solubility and high permeability, while drugs in group III have high solubility and low permeability. Drugs in group IV have low bioavailability and require various techniques to enhance their delivery due to their low solubility and permeability. AREAS COVERED: Bile acids are commonly known as biological molecules with surfactant capabilities and continue to be underutilized in enhancing the pharmaceutical profile of drugs. Hence, this review will explore some of the common drug delivery methods and will focus on the use of bile acids and various applications of nanotechnology to enhance drug delivery, including lipid nanotechnology, as well as carbon nanotubes and quantum dots. The authors aim to provide more insights into drug delivery research and contribute to the development of novel drug delivery strategies.

methodA literature search was conducted using ProQuest and PubMed, covering publications up to 10 years. Older references were included as appropriate.

Indexed as

Bile Acids and SaltsDrug Delivery SystemsNanotechnologyAnimalsBiological AvailabilityHumansNanotubes, CarbonPermeabilityPharmaceutical PreparationsQuantum DotsSolubilityBile Acids and SaltsNanotubes, CarbonPharmaceutical PreparationsBile acidsbiopharmaceutics classification systemcarbon nanotubesdrug deliverynanotechnologyquantum dots

Identifiers

PMID42287172
PMCPMC13349015

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.